EA011480B1 - Поливалентная вакцинная композиция - Google Patents

Поливалентная вакцинная композиция Download PDF

Info

Publication number
EA011480B1
EA011480B1 EA200501070A EA200501070A EA011480B1 EA 011480 B1 EA011480 B1 EA 011480B1 EA 200501070 A EA200501070 A EA 200501070A EA 200501070 A EA200501070 A EA 200501070A EA 011480 B1 EA011480 B1 EA 011480B1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
vaccine
immunogenic composition
composition according
dose
Prior art date
Application number
EA200501070A
Other languages
English (en)
Russian (ru)
Other versions
EA200501070A1 (ru
Inventor
Доминик Бутрио
Карин Капио
Пьер Мишель Десмон
Доминик Лемуан
Жан Пулман
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA011480(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0015999.6A external-priority patent/GB0015999D0/en
Priority claimed from GB0108363A external-priority patent/GB0108363D0/en
Priority claimed from GBGB0108364.1A external-priority patent/GB0108364D0/en
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200501070A1 publication Critical patent/EA200501070A1/ru
Publication of EA011480B1 publication Critical patent/EA011480B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
EA200501070A 2000-06-29 2001-06-27 Поливалентная вакцинная композиция EA011480B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0015999.6A GB0015999D0 (en) 2000-06-29 2000-06-29 Novel compounds
GB0108363A GB0108363D0 (en) 2001-04-03 2001-04-03 Vaccine composition
GBGB0108364.1A GB0108364D0 (en) 2001-04-03 2001-04-03 Vaccine composition

Publications (2)

Publication Number Publication Date
EA200501070A1 EA200501070A1 (ru) 2006-02-24
EA011480B1 true EA011480B1 (ru) 2009-04-28

Family

ID=27255788

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200501070A EA011480B1 (ru) 2000-06-29 2001-06-27 Поливалентная вакцинная композиция
EA200201240A EA006313B1 (ru) 2000-06-29 2001-06-27 Поливалентные иммуногенные композиции и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200201240A EA006313B1 (ru) 2000-06-29 2001-06-27 Поливалентные иммуногенные композиции и способы их применения

Country Status (34)

Country Link
US (2) US20030180316A1 (cg-RX-API-DMAC7.html)
EP (4) EP2279748A1 (cg-RX-API-DMAC7.html)
JP (2) JP4870895B2 (cg-RX-API-DMAC7.html)
KR (3) KR100898845B1 (cg-RX-API-DMAC7.html)
CN (2) CN1449293B (cg-RX-API-DMAC7.html)
AP (1) AP1695A (cg-RX-API-DMAC7.html)
AT (1) ATE534402T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001281895C1 (cg-RX-API-DMAC7.html)
BG (2) BG66238B1 (cg-RX-API-DMAC7.html)
BR (2) BRPI0112057B8 (cg-RX-API-DMAC7.html)
CA (2) CA2412497C (cg-RX-API-DMAC7.html)
CY (2) CY1112280T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20024224A3 (cg-RX-API-DMAC7.html)
DK (2) DK1946769T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3399A1 (cg-RX-API-DMAC7.html)
EA (2) EA011480B1 (cg-RX-API-DMAC7.html)
EG (1) EG24742A (cg-RX-API-DMAC7.html)
ES (2) ES2375704T5 (cg-RX-API-DMAC7.html)
HU (3) HU227893B1 (cg-RX-API-DMAC7.html)
IL (2) IL153506A0 (cg-RX-API-DMAC7.html)
MA (1) MA25824A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000198A (cg-RX-API-DMAC7.html)
MY (1) MY133981A (cg-RX-API-DMAC7.html)
NO (1) NO332495B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523319A (cg-RX-API-DMAC7.html)
OA (1) OA12302A (cg-RX-API-DMAC7.html)
PE (1) PE20020126A1 (cg-RX-API-DMAC7.html)
PL (2) PL210015B1 (cg-RX-API-DMAC7.html)
PT (2) PT1946769E (cg-RX-API-DMAC7.html)
SI (2) SI1296715T2 (cg-RX-API-DMAC7.html)
SK (1) SK288007B6 (cg-RX-API-DMAC7.html)
UA (2) UA76952C2 (cg-RX-API-DMAC7.html)
UY (1) UY26801A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002000249A2 (cg-RX-API-DMAC7.html)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540795B2 (ja) * 2000-03-10 2010-09-08 一般財団法人阪大微生物病研究会 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン
PT1946769E (pt) 2000-06-29 2012-06-27 Smithkline Beecham Biolog Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100947757B1 (ko) 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드―단백질 접합체 백신
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
EP2332573A1 (en) 2001-05-31 2011-06-15 Novartis Vaccines and Diagnostics, Inc. Chimeric alphavirus replicon particles
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
US20060147466A1 (en) * 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
EP2353608B1 (en) 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
ATE352316T1 (de) * 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006516609A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 粘膜髄膜炎菌性ワクチン
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
CN1819843A (zh) 2003-05-07 2006-08-16 安万特巴斯德公司 增强脑膜炎球菌疫苗接种免疫原性的方法
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US20050019337A1 (en) * 2003-06-23 2005-01-27 Ryall Robert P. Immunization method against Neisseria meningitidis serogroups A and C
PT1961426E (pt) * 2003-10-02 2011-06-28 Novartis Vaccines & Diagnostic Vacinas combinadas contra a meningite
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23404A1 (es) * 2003-11-19 2009-08-04 Ct Ingenieria Genetica Biotech Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP1740217B1 (en) 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningococcal conjugate vaccination
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI511739B (zh) * 2005-04-08 2015-12-11 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
ATE536884T1 (de) * 2005-06-27 2011-12-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
CN1709505B (zh) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20090010959A1 (en) * 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2633789A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
AU2007206114B2 (en) * 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP1872791A1 (en) 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
NZ575273A (en) * 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
WO2008135514A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
AU2008259423A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
HRP20151122T1 (hr) 2007-06-26 2015-11-20 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009262893B2 (en) * 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
MX2012013664A (es) * 2010-06-04 2013-01-24 Wyeth Llc Formulaciones de vacuna.
PT3023106T (pt) * 2010-12-14 2019-11-04 Glaxosmithkline Biologicals Sa Composição antigénica de micobactéria
RU2705163C2 (ru) 2011-01-05 2019-11-05 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
CA2863178C (en) * 2012-01-30 2021-04-06 Serum Institute Of India Ltd. Immunogenic composition
EP2822584A1 (en) * 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
WO2014057132A1 (en) 2012-10-12 2014-04-17 Novartis Ag Non-cross-linked acellular pertussis antigens for use in combination vaccines
JP6236086B2 (ja) * 2012-10-17 2017-11-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MX362793B (es) 2013-03-08 2019-02-13 Janssen Vaccines & Prevention Bv Vacuna acelular contra pertussis.
CN105492454B (zh) * 2013-07-07 2019-09-27 马普科技促进协会 合成针对1型肺炎链球菌的疫苗
BR112016002354A2 (pt) 2013-08-05 2017-09-12 Glaxosmithkline Biologicals Sa composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
KR20190049940A (ko) * 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP7001687B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
SG11201900789VA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
PE20201338A1 (es) 2017-12-06 2020-11-25 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos
US11123417B2 (en) 2018-02-05 2021-09-21 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP7288451B2 (ja) 2018-02-05 2023-06-07 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質複合体組成物
WO2019203599A1 (ko) 2018-04-18 2019-10-24 에스케이바이오사이언스 주식회사 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
WO2019212844A1 (en) * 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
KR20200005458A (ko) 2018-07-06 2020-01-15 주식회사 유바이오로직스 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
US20210401960A1 (en) * 2018-11-10 2021-12-30 Bharat Biotech International Limited Multivalent glycoconjugates immunogenic compositions
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN114302737A (zh) 2019-05-20 2022-04-08 索利吉尼克斯公司 制造三价线状病毒疫苗的组合物和方法
CN111821432B (zh) * 2020-08-05 2022-10-18 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合疫苗
WO2025109417A1 (en) * 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497525A2 (en) * 1991-01-28 1992-08-05 Merck & Co. Inc. Pneumococcal polysaccharide conjugate vaccine
WO1993024148A1 (en) * 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Combined vaccines comprising hepatitis b surface antigen and other antigens
EP0594950A1 (en) * 1992-10-27 1994-05-04 American Cyanamid Company Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
WO1997000697A1 (en) * 1995-06-23 1997-01-09 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
WO1999013906A1 (en) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
WO1999048525A1 (en) * 1998-03-25 1999-09-30 Smithkline Beecham Biologicals S.A. Hib/dtpa vaccine composition and methods of preparation

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) * 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
JPS6061288A (ja) * 1983-09-13 1985-04-09 Fuji Photo Film Co Ltd 感熱記録材料
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
AU671649B2 (en) 1992-06-18 1996-09-05 President And Fellows Of Harvard College Diphtheria toxin vaccines
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
ES2210262T3 (es) * 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
EP0973911A1 (en) 1997-01-30 2000-01-26 Imperial College Of Science, Technology & Medicine MUTANT $i(msbB) or $i(htrB) GENES
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1946769E (pt) 2000-06-29 2012-06-27 Smithkline Beecham Biolog Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
ATE536884T1 (de) * 2005-06-27 2011-12-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20090010959A1 (en) * 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
CA2633789A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
JP4858611B2 (ja) * 2007-03-14 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
WO2008135514A1 (en) * 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
AU2008259423A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
HRP20151122T1 (hr) * 2007-06-26 2015-11-20 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497525A2 (en) * 1991-01-28 1992-08-05 Merck & Co. Inc. Pneumococcal polysaccharide conjugate vaccine
WO1993024148A1 (en) * 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Combined vaccines comprising hepatitis b surface antigen and other antigens
EP0594950A1 (en) * 1992-10-27 1994-05-04 American Cyanamid Company Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
WO1997000697A1 (en) * 1995-06-23 1997-01-09 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
WO1999013906A1 (en) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
WO1999048525A1 (en) * 1998-03-25 1999-09-30 Smithkline Beecham Biologicals S.A. Hib/dtpa vaccine composition and methods of preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDRE F.E.: "Development and clinical application of new polyvalent combined paediatric vaccines", VACCINE, vol. 17, no. 13-14, 26 March 1999 (1999-03-26), pages 1620-1627, XP004158296 *
PAPAEVANGELOU G.: "Current combined vaccines with hepatitis B", VACCINE, vol. 16, no. Suppl., November 1998 (1998-11), pages S69-S72, XP002194358 *
PINES E. ET AL.: "New acellular pertussis-containing paediatric combined vaccines", VACCINE, vol. 17, no. 13-14, 26 March 1999 (1999-03-26), pages 1650-1656, XP004158300 *

Also Published As

Publication number Publication date
UA85853C2 (uk) 2009-03-10
NO20026175D0 (no) 2002-12-20
BR122012003821B8 (pt) 2021-05-25
BG107422A (bg) 2003-09-30
EA200201240A1 (ru) 2003-06-26
EP1946769A2 (en) 2008-07-23
JP2010163453A (ja) 2010-07-29
ES2375704T5 (es) 2016-03-03
CA2783274C (en) 2018-08-07
EP2277541A1 (en) 2011-01-26
AP1695A (en) 2006-12-17
DK1296715T4 (en) 2016-03-07
KR20030024714A (ko) 2003-03-26
HU1000594D0 (en) 2010-12-28
PL393584A1 (pl) 2011-05-23
EP1296715A2 (en) 2003-04-02
BRPI0112057B1 (pt) 2016-10-04
OA12302A (en) 2003-10-24
EP1296715B2 (en) 2015-12-23
WO2002000249A2 (en) 2002-01-03
US9233151B2 (en) 2016-01-12
NO332495B1 (no) 2012-10-01
KR20070091698A (ko) 2007-09-11
MXPA03000198A (es) 2004-09-13
CA2412497C (en) 2012-10-02
HU227613B1 (en) 2011-09-28
CY1112280T1 (el) 2015-12-09
PE20020126A1 (es) 2002-04-27
ES2385100T3 (es) 2012-07-18
BG110518A (bg) 2010-04-30
HK1055244A1 (en) 2004-01-02
CN101708333A (zh) 2010-05-19
KR100898845B1 (ko) 2009-05-21
BR122012003821B1 (pt) 2020-09-01
SI1946769T1 (sl) 2012-07-31
WO2002000249A3 (en) 2002-06-13
EA006313B1 (ru) 2005-10-27
DK1296715T3 (da) 2012-02-13
KR100837917B1 (ko) 2008-06-13
SI1296715T1 (sl) 2012-03-30
AU8189501A (en) 2002-01-08
NO20026175L (no) 2003-02-26
BG66238B1 (bg) 2012-08-31
ATE534402T1 (de) 2011-12-15
DK1946769T3 (da) 2012-07-16
SK18432002A3 (sk) 2003-08-05
EG24742A (en) 2010-07-14
ES2375704T3 (es) 2012-03-05
AU2001281895C1 (en) 2005-10-27
CN1449293A (zh) 2003-10-15
EP1946769A3 (en) 2008-07-30
SI1296715T2 (sl) 2016-03-31
PT1946769E (pt) 2012-06-27
PL210015B1 (pl) 2011-11-30
UA76952C2 (uk) 2006-10-16
KR20080052700A (ko) 2008-06-11
HU227893B1 (en) 2012-05-29
US20030180316A1 (en) 2003-09-25
US20120207780A1 (en) 2012-08-16
IL153506A0 (en) 2003-07-06
EA200501070A1 (ru) 2006-02-24
BG66249B1 (en) 2012-09-28
CA2412497A1 (en) 2002-01-03
DZ3399A1 (fr) 2002-01-03
PT1296715E (pt) 2012-01-19
HUP0301413A3 (en) 2010-01-28
JP4870895B2 (ja) 2012-02-08
BR0112057A (pt) 2003-06-17
MY133981A (en) 2007-11-30
CA2783274A1 (en) 2002-01-03
EP2279748A1 (en) 2011-02-02
AP2002002700A0 (en) 2002-12-31
CN1449293B (zh) 2012-08-22
SK288007B6 (sk) 2012-10-02
HU228384B1 (en) 2013-03-28
MA25824A1 (fr) 2003-07-01
PL360265A1 (en) 2004-09-06
UY26801A1 (es) 2002-01-31
HU1000593D0 (en) 2010-12-28
HUP0301413A1 (hu) 2003-08-28
IL153506A (en) 2009-06-15
CN101708333B (zh) 2014-03-26
CZ20024224A3 (cs) 2003-05-14
CY1112915T1 (el) 2016-04-13
BRPI0112057B8 (pt) 2021-05-25
EP1946769B1 (en) 2012-05-30
EP1296715B1 (en) 2011-11-23
JP2004501873A (ja) 2004-01-22
NZ523319A (en) 2006-01-27
JP5346308B2 (ja) 2013-11-20
AU2001281895B2 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
EA011480B1 (ru) Поливалентная вакцинная композиция
ES2384065T3 (es) Composición de vacuna multivalente
EA012506B1 (ru) Иммуногенная композиция
HU229968B1 (hu) Sztreptokokkusz oltóanyag
PT1409013E (pt) Vacinas compreendendo os adjuvantes alumínio e histidina
HK1114779B (en) Multivalent vaccine composition

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MK4A Patent expired

Designated state(s): BY KZ RU